- Article metrics
- Last updated: Tue, 20 May 2025 9:42:38 Z
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
Access & Citations
-
- 1455
- Article Accesses
-
- Data not available
- Web of Science
-
- Data not available
- CrossRef
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.